<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124341">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01861873</url>
  </required_header>
  <id_info>
    <org_study_id>210982</org_study_id>
    <nct_id>NCT01861873</nct_id>
  </id_info>
  <brief_title>Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases</brief_title>
  <official_title>Phase 2 Study: Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Anatomical (traditional) stereotactic body radio therapy(SBRT) treatment
      planning assumes homogenous distribution of function in the normal liver tissue. In
      functional treatment planning, additional information on distribution of the function
      derived from functional imaging of normal tissue is taken into account. by functional
      treatment planning it becomes possible to prioritize and spare the best functioning part of
      an organ.

      Aim: To test whether functional treatment planning based on 18-FDGal PET/CT may spare the
      best functioning liver tissue.

      Endpoints: Reduction in hepatic systemic clearance (K) in the dynamic 18-FDGal PET/CT scan
      one month after SBRT compared to the baseline status in sub-volumes recieving 15 Gy or
      higher. Secondly, the investigators will evaluate the toxicity to SBRT by a toxicity scoring
      system that includes biochemical measures as well as symptomatic scores.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>volumetric uptake values of 18-FDGal will be measured and the 18-FDGal PET/CT one month after stereotactic body radioation therapy will be compared to the baseline status in sub-volumes receiving more than 15 Gy</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate toxicity to SBRT by toxicity scoring system that includes biochemical measures as well as symptomatic scores.</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>liver metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>measuring liver function by PET/CT at patients where SBRT is planned for liver metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>measuring liver function by 18-FDGal PET/CT</intervention_name>
    <arm_group_label>liver metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status &gt;2

          -  liver metastases refereed for SBRT

        Exclusion Criteria:

          -  pregnancy

          -  claustrophobia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mette Marie Fode, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver function</keyword>
  <keyword>galactose</keyword>
  <keyword>18-F-deoxy-galactose</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
